Oragenics (OGEN) AI Stock Analysis

• Market Cap: $3.83M
• Dividend Yield: N/A
• Average Volume (3M): 211.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.06
• Revenue Growth: N/A
• EPS Growth: 90.27%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.85
• Shares Outstanding: 4,168,223
• 10 Day Avg. Volume: 326,842
• 30 Day Avg. Volume: 211,777
• PEG Ratio: 0.08
• Price to Book (P/B): -346.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.53
• Enterprise Value/Market Cap: 1.29
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.71
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 29 Underperform
• Price Target: ―

Oragenics exhibits significant financial distress, with ongoing unprofitability, negative equity, and cash flow issues, contributing to a low financial performance score. The technical indicators reflect a weak stock momentum, further exacerbating the negative outlook. Valuation metrics are unfavorable due to negative earnings and lack of dividends, highlighting the challenges facing the company. Overall, the stock's fundamental and technical weaknesses are significant, resulting in a low overall score.

Positive Factors

Leadership Change

The appointment of Janet Huffman as CEO and CFO may bring strategic leadership and operational improvements, potentially enhancing the company's focus on financial restructuring and growth.

Strategic Partnerships

Oragenics' focus on R&D collaborations and strategic partnerships can drive innovation and provide financial support, aiding in the development and commercialization of its proprietary products.

Lantibiotic Platform

The proprietary lantibiotic platform positions Oragenics to address antibiotic resistance, offering a competitive advantage in developing novel antibiotics with unique mechanisms of action.

Negative Factors

Financial Distress

Ongoing financial distress, characterized by persistent losses and negative equity, threatens long-term viability and limits the company's ability to invest in growth opportunities.

Negative Cash Flow

Consistently negative operating cash flow indicates challenges in generating sufficient cash to cover operational expenses, potentially impacting future growth and sustainability.

Declining Revenues

Declining revenues highlight difficulties in product commercialization and market penetration, which are critical for achieving financial stability and growth.

Oragenics Business Overview & Revenue Model

Company Description

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

How the Company Makes Money

Oragenics generates revenue primarily through research and development collaborations, grants, and potential milestone payments from strategic partnerships. The company focuses on advancing its product candidates through various stages of clinical trials, aiming to out-license or co-develop these products with larger pharmaceutical companies. Revenue is also derived from government and private funding initiatives that support the development of new antibiotics and treatments for infectious diseases. Long-term, Oragenics aims to commercialize its proprietary products, thereby generating revenue through product sales and royalties.

Oragenics Financial Statement Overview

Summary

Oragenics is facing significant financial challenges, with persistent losses, negative equity, and cash flow issues. The company's financial position is fragile, with minimal revenues and ongoing reliance on financing activities to sustain operations. Improving operational efficiency and generating revenue growth are crucial to enhancing financial stability.

Income Statement

The company has experienced declining revenues over the years, with no revenues in 2024 and minimal revenues in previous years. Gross profit margins are negative, indicating cost inefficiencies or low sales volumes. The company has consistently reported negative EBIT and net income, reflecting ongoing unprofitability.

Balance Sheet

The balance sheet shows a negative stockholders' equity in 2024, indicating potential financial distress. The debt-to-equity ratio is not meaningful due to negative equity, though total liabilities have decreased over time. The company has maintained a high cash balance, which provides some liquidity despite ongoing losses.

Cash Flow

Operating cash flow has been negative, reflecting cash outflows from operations, though financing activities have provided some cash inflows. Free cash flow is consistently negative, which underscores the challenges in generating sufficient cash to cover operating and potential capital expenditures.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	-22.11M
EBITDA	-6.99M	-10.54M	-20.60M	-14.23M	-15.65M	-26.59M
Net Income	-10.90M	-10.57M	-20.66M	-14.29M	-15.71M	-26.43M
Balance Sheet
Total Assets	12.71M	1.47M	4.97M	14.76M	28.23M	18.68M
Cash, Cash Equivalents and Short-Term Investments	11.40M	864.84K	3.48M	11.43M	27.27M	17.64M
Total Debt	394.84K	328.53K	322.51K	624.53K	797.21K	898.92K
Total Liabilities	2.87M	1.68M	1.80M	1.75M	1.74M	1.84M
Stockholders Equity	9.83M	-211.88K	3.17M	13.01M	26.49M	16.84M
Cash Flow
Free Cash Flow	-8.43M	-8.60M	-8.29M	-15.36M	-13.51M	-16.95M
Operating Cash Flow	-8.43M	-8.60M	-7.29M	-15.23M	-13.47M	-16.95M
Investing Cash Flow	0.00	0.00	-936.28K	-115.52K	-43.88K	0.00
Financing Cash Flow	16.69M	5.98M	283.88K	-494.92K	23.14M	16.32M

Oragenics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.92
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OGEN, the sentiment is Neutral. The current price of 0.92 is above the 20-day moving average (MA) of 0.85, below the 50-day MA of 0.93, and below the 200-day MA of 2.37, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 57.51 is Neutral, neither overbought nor oversold. The STOCH value of 92.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OGEN.

Oragenics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INM	44 Neutral	$3.17M	-0.15	-82.17%	―	-3.27%	51.83%
GRI	42 Neutral	$3.32M	―	-397.84%	―	―	98.22%
ONCO	33 Underperform	$2.47M	>-0.01	-263.57%	―	-34.58%	96.41%
OGEN	29 Underperform	$3.83M	-0.06	-168.95%	―	―	90.27%

Oragenics Corporate Events

Oragenics Adjusts Executive Compensation Plan

On December 11, 2025, Oragenics, Inc. announced adjustments to its executive compensation plan. The Board of Directors approved a 5% salary increase for CEO Janet Huffman, effective January 1, 2026, raising her annual base salary to $341,250. Additionally, she received a bonus of $110,500 based on her performance. The Board also granted her options to purchase 250,000 shares of company stock, with vesting over three years. Non-Employee Directors received options for 125,000 shares, which vested immediately. Natasha Giordano, appointed to the Board on September 1, 2025, was awarded an onboarding stock option valued at $30,000, which vested immediately.

Oragenics Regains NYSE Compliance After Public Offering

On October 16, 2025, Oragenics settled a dispute with Ladenburg Thalmann & Co., Inc., agreeing to pay $700,000 to resolve claims related to an investment banking agreement from December 2022. This settlement followed a confidential arbitration initiated by Oragenics in March 2024. Additionally, Oragenics announced on October 21, 2025, that it regained compliance with NYSE American listing standards, following a successful $16.5 million public offering in July 2025. This compliance restoration allows the company to focus on advancing its lead clinical program, ONP-002, for treating traumatic brain injuries.